母体血浆可溶性神经纤毛蛋白-1在合并脐动脉多普勒异常的胎儿生长受限中下调:一项初步研究
这项前瞻性病例对照初步研究纳入40例单胎妊娠(20例FGR,20例对照),检测母体血浆sNRP1。结果与假设相反,FGR组sNRP1显著低于对照组(137.4±44.8 pg/mL vs 166.7±36.9 pg/mL,P=0.03);但在脐动脉多普勒正常的FGR与对照间无差异,sNRP1在脐动脉血流异常FGR中进一步降低。
要点
- FGR合并脐动脉血流异常时母体血浆sNRP1显著降低。
- 脐动脉多普勒正常的FGR与对照sNRP1无显著差异。
- sNRP1或可作为FGR伴血流异常的候选生物标志物。
核心结论
- 合并胎儿胎盘循环障碍的生长受限妊娠中,母体血浆sNRP1浓度显著降低。
- sNRP1可能参与调控胎儿生长,并有望作为FGR的生物标志物。
研究设计与样本
- 前瞻性病例对照初步研究,2015年1月至2017年5月在学术围产中心随访。
- 共40例单胎妊娠,FGR组20例,无并发症对照组20例,孕周24+0至40+0周。
- FGR定义为超声估测胎儿体重低于同孕周第10百分位,对照按母亲年龄和评估时孕周匹配。
主要发现
- 母体血浆sNRP1在FGR组显著低于对照组(137.4±44.8 pg/mL vs 166.7±36.9 pg/mL;P=0.03)。
- 对照组与脐动脉多普勒正常的FGR组之间sNRP1浓度无显著差异。
- FGR伴脐动脉收缩/舒张比值升高者sNRP1下调(P=0.023)。
- FGR伴脐动脉舒张末期血流缺失或反向者sNRP1下调(P=0.005)。
关键数值与推荐
- FGR定义:超声估测胎儿体重低于同孕周第10百分位。
- sNRP1检测采用市售ELISA法测定母体血浆。
临床怎么用
- 对FGR合并脐动脉多普勒异常者,可关注母体血浆sNRP1降低所提示的胎儿胎盘循环障碍。
- 脐动脉多普勒正常的小于胎龄儿与FGR的sNRP1表现不同,提示需结合血流评估区分生理性小与病理性FGR。
局限性
- 本研究为初步研究,样本量小(共40例)。
- 研究结果与初始假设相反,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Placental expression of neuropilin-1 (NRP1), a proangiogenic member of the vascular endothelial growth factor receptor family involved in sprouting angiogenesis, was recently discovered to be downregulated in pregnancies with fetal growth restriction (FGR) and abnormal umbilical artery (UA) Doppler. Soluble NRP1 (sNRP1) is an antagonist to NRP1; however, little is known about its role in normal and FGR pregnancies. This study tested the hypotheses that, first, sNRP1 would be detectable in maternal circulation and, second, its concentration would be upregulated in FGR pregnancies compared to those with normal fetal growth and this would correlate with the severity of the disease as assessed by UA Doppler. METHODS: This was a prospective case-control pilot study of 40 singleton pregnancies (20 FGR cases and 20 uncomplicated controls) between 24 + 0 and 40 + 0 weeks' gestation followed in an academic perinatal center from January 2015 to May 2017. FGR was defined as an ultrasound-estimated fetal weight < 10th percentile for gestational age. The control group was matched to the FGR group for maternal age and gestational age at assessment. Fetal ultrasound biometry and UA Doppler were performed using standard protocols. Maternal plasma sNRP1 measurements were performed using a commercially available ELISA. RESULTS: Contrary to the study hypothesis, maternal plasma sNRP1 levels were significantly decreased in FGR pregnancies as compared to those with normal fetal growth (137.4 ± 44.8 pg/mL vs 166.7 ± 36.9 pg/mL; P = 0.03). However, there was no significant difference in sNRP1 concentration between the control group and FGR pregnancies that had normal UA Doppler. Plasma sNRP1 was downregulated in FGR pregnancies with elevated UA systolic/diastolic ratio (P = 0.023) and those with UA absent or reversed end-diastolic flow (P = 0.005) in comparison to FGR pregnancies with normal UA Doppler. This suggests that biometrically small fetuses without hemodynamic compromise are small-for-gestational age rather than FGR. CONCLUSIONS: This study demonstrated a significant decrease in maternal plasma sNRP1 concentration in growth-restricted pregnancies with fetoplacental circulatory compromise. These findings suggest a possible role of sNRP1 in modulating fetal growth and its potential as a biomarker for FGR. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Porter B, Maulik D, Babbar S, et al. Maternal plasma soluble neuropilin-1 is downregulated in fetal growth restriction complicated by abnormal umbilical artery Doppler: a pilot study. Ultrasound Obstet Gynecol. 2021. PMID: 33533520. doi:10.1002/uog.23605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。